# Palacaparib

Source: https://onco.cc/drugs/palacaparib/  
OnCo record `palacaparib` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Palacaparib is an experimental DNA-repair inhibitor designed to reach the brain and selectively block PARP1.

## Summary

The primary discovery publication identifies AZD9574/palacaparib as a brain-penetrant PARP1-selective inhibitor. CERTIS1 (NCT05417594) is recruiting with 695 planned participants and was updated in October 2026. It studies monotherapy and combinations including temozolomide, trastuzumab deruxtecan and datopotamab deruxtecan. A registry-wide recruiting state does not confirm a specific local site or available slot. Brain exposure and PARP1 selectivity are development features; human superiority, marrow sparing and a breast-cancer indication are not established.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-10-06
- Tags: pipeline; ctgov-ingest
- Code: AZD9574
- Modality: small molecule
- Mechanism: PARP1-selective, brain-penetrant inhibitor and trapper (AZD9574).

## Sources

- ClinicalTrials.gov: trials of Palacaparib: https://clinicaltrials.gov/search?intr=AZD9574
- ClinicalTrials.gov NCT05417594: https://clinicaltrials.gov/study/NCT05417594
- Primary discovery publication: https://doi.org/10.1021/acs.jmedchem.4c01725

## Connected records

- cancers: [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- targets: [PARP](https://onco.cc/targets/parp/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)
- trials: [A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies](https://onco.cc/trials/nct05123482/), [Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors](https://onco.cc/trials/nct05797168/), [Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer](https://onco.cc/trials/nct07590934/), [Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer](https://onco.cc/trials/nct07181161/), [Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies](https://onco.cc/trials/nct05417594/)

---
JSON: https://onco.cc/api/v1/entities/palacaparib.json